Skip to content
Head to head

Xencor vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: XNCR · VRTX

Updated 9 minutes ago

1-year performance, rebased to 100

XNCR +112.9%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
XNCRVRTX
Snapshot
Sector--Biotechnology
Last price33.26515.02
Change today-2.21%-1.08%
1-year return+113.5%+22.0%
Market cap$2.50B$130.58B
52-week range10.38 – 40.60412.27 – 568.67
Valuation
P/E (TTM)-21.3233.14
P/E percentile, own 5-yr range10th99th
P/B4.456.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-1.2415.32
Net profit (TTM)$-93.05M$3.88B
Revenue (TTM)$200.49M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+454.9%+11.8%
Gross margin--85.5%
Operating margin-72.7%33.1%
Net margin-58.8%30.7%
Free cash flow (TTM)$-176.45M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership113.1%96.8%
Insider activity (12mo)27 buy / 23 sell28 buy / 22 sell
Short interest (% of float)17.3%1.9%
Analyst consensus80% buy / 20% hold (10)95% buy / 5% hold (21)
Analyst price target$41 (+24%)$624 (+21%)
StockVane view
StockVane Quant RatingC (98)C (68)
Company
Employees2606,400
Founded19971989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.